![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1375139
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¿¹Ãø(-2028³â) : Áö¿ªº° ºÐ¼® - Á¦Ç° À¯Çü, ÀÀ¿ë ºÐ¾ß ¹× ÃÖÁ¾ »ç¿ëÀÚº°North America Neurotoxins Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product Type, Application, and End User |
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº 2023³â 48¾ï 129¸¸ ´Þ·¯¿¡¼ 2028³â 84¾ï 1,695¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2028³â±îÁö 11.9%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
Çõ½ÅÀûÀÎ ÆäÀÌ¼È ¿¡½ºÅׯ½ Á¦Ç°ÀÇ µîÀåÀ¸·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå Ȱ¼ºÈ
Àüü ½Å°æµ¶ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¾È¸é ¹Ì¿ë¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ±âÇϱ޼öÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³â 3¿ù, Aquavit Pharmaceuticals, Inc. ÀÓ»ó½ÃÇè¿ë ½Å¾à(IND) ½ÅûÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº Ŭ·Î½ºÆ®¸®µð¿ò º¸Åø¸®´®±ÕÀÌ »ý»êÇÏ´Â ½Å°æµ¶¿¡¼ À¯·¡ÇÑ 900kDaÀÇ ´Ü¹éÁú º¹ÇÕü¸¦ °í¼øµµ·Î Á¤Á¦ÇØ ÀÓ»ó½ÃÇèÀ» ¿Ï·áÇÑ ÁÖ»çÁ¦Çü ½Å°æÁ¶ÀýÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ¾ÆÄí¾ÆºñÆ®´Â DTX-022¸¦ µµÀÔÇØ ÀÓ»óÀ» °¡¼ÓÈÇϰí ÀÖÀ¸¸ç, ÃÖÁ¾ ½ÂÀÎ ½Ã ¼¼°è ÃÖÃÊÀÇ ¹ü¾È¸é ¹Ì·®ÁÖ»çÁ¦ ½Å°æµ¶À¸·Î ÀÎÁ¤¹Þ°Ô µË´Ï´Ù. ¸¶Âù°¡Áö·Î, üÁß °¨·® Æ®·»µå°¡ Áö¼ÓµÇ¸é¼ ºñħ½ÀÀû ½Ã¼úÀ» ¿øÇϴ ȯÀÚµé »çÀÌ¿¡¼ À§ º¸Å彺°¡ Àαâ ÀÖ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. À§ º¸Å彺´Â ³»½Ã°æ ±â¼úÀ» ÅëÇØ ƯÁ¤ À§ ºÎÀ§¿¡ º¸Å彺¸¦ ÁÖÀÔÇÏ´Â ½Ã¼úÀÔ´Ï´Ù. ÀÌ ±â¼úÀº À§ ±ÙÀ°ÀÇ ¼öÃàÀ» Á¦ÇÑÇÕ´Ï´Ù. ÀÌ Á¦ÇÑÀ¸·Î ÀÎÇØ À§ ¹èÃâ °úÁ¤¿¡ ½Ã°£ÀÌ °É¸®±â ¶§¹®¿¡ ȯÀÚ´Â ´õ ¿À·¡ Æ÷¸¸°¨À» ´À³¥ ¼ö ÀÖÀ¸¸ç, ±× °á°ú ½Ä¿åÀÌ °¨¼ÒÇÏ°í °íÇ÷¾Ð, ´ç´¢º´°ú °°Àº üÁß °ü·Ã °Ç° ¹®Á¦ ¹× »ýȰ½À°üº´À» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ Çõ½ÅÀûÀÎ ¾È¸é ¹Ì¿ë Á¦Ç°ÀÇ ÃâÇöÀº ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀÇ ¼ºÀå¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå °³¿ä
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº ½Å°æµ¶ÀÇ °¡Àå Å©°í ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº Á¦Ç° Ãâ½Ã Áõ°¡, ´Ù¾çÇÑ ±ÙÀ° Áúȯ¿¡ ´ëÇÑ ½Å°æµ¶ÀÇ FDA ½ÂÀÎ Áõ°¡, °í·ÉÈ Àα¸ Áõ°¡, ºñ¼ö¼úÀû ¶Ç´Â Àúħ½ÀÀû ¹Ì¿ë ½Ã¼ú Áõ°¡, ¹Ì¿ë ½Ã¼ú Áõ°¡, Àúħ½ÀÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¼öÀÍ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¼¼ºÐÈ
ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ºÐ·ùµË´Ï´Ù. Á¦Ç° À¯Çü¿¡ µû¶ó ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº º¸Å彺, µð½ºÆ÷Æ®, Á¦³ë¹Î ¹× ±âŸ·Î ¼¼ºÐȵ˴ϴÙ. º¸Å彺 ºÎ¹®Àº 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
¿ëµµº°·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº Ä¡·á¿ë°ú ¹Ì¿ë¿ëÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â Ä¡·á ºÎ¹®ÀÌ ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ÇǺΰú Ŭ¸®´Ð, ±âŸ·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î´Â ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹ÀÌ 2023³â ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH &Co KGaA, Metabiologics, Revance Therapeutics Inc µîÀÌ ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.
The North America neurotoxins market is expected to grow from US$ 4,801.29 million in 2023 to US$ 8,416.95 million by 2028. It is estimated to grow at a CAGR of 11.9% from 2023 to 2028.
Emergence of Innovative Facial Aesthetic Products Fuels North America Neurotoxins Market
The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"-a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the North America neurotoxin market to grow.
North America Neurotoxins Market Overview
The North America neurotoxin market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for neurotoxins. The market growth in the region is attributed to the increasing product launches, growing FDA approvals for neurotoxins for various muscular conditions, rising aging population, increasing numbers of non-surgical or minimally invasive cosmetic procedures, increasing number of aesthetic procedures, and growing demand for minimally invasive therapeutics.
North America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)
North America Neurotoxins Market Segmentation
The North America neurotoxins market is segmented into product type, application, end user, and country. Based on product type, the North America neurotoxins market is sub segmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the North America neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.
Based on end user, the North America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the North America neurotoxins market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2023.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH & Co KGaA, Metabiologics, and Revance Therapeutics Inc are among the leading companies operating in the North America neurotoxins market.